The CO-releasing molecule CORM-3 protects adult cardiomyocytes against hypoxia-reoxygenation by modulating pH restoration

Eur J Pharmacol. 2019 Nov 5:862:172636. doi: 10.1016/j.ejphar.2019.172636. Epub 2019 Sep 3.

Abstract

Several studies have reported that CORM-3, a water-soluble carbon monoxide releasing molecule, elicits cardioprotection against myocardial infarction but the mechanism remains to be investigated. Numerous reports indicate that inhibition of pH regulators, the Na+/H+ exchanger (NHE) and Na+/HCO3- symporter (NBC), protect cardiomyocytes from hypoxia/reoxygenation injury by delaying the intracellular pH (pHi) recovery at reperfusion. Our goal was to explore whether CORM-3-mediated cytoprotection involves the modulation of pH regulation. When added at reoxygenation, CORM-3 (50 μM) reduced the mortality of cardiomyocytes exposed to 3 h of hypoxia and 2 h of reoxygenation in HCO3--buffered solution. This effect was lost when using inactive iCORM-3, which is depleted of CO and used as control, thus implicating CO as the mediator of this cardioprotection. Interestingly, the cardioprotective effect of CORM-3 was abolished by switching to a bicarbonate-free medium. This effect of CORM-3 was also inhibited by 5-hydroxydecanoate, a mitochondrial ATP-dependent K+ (mKATP) channel inhibitor (500 μM) or PD098059, a MEK1/2 inhibitor (10 μM). In additional experiments and in the absence of hypoxia-reoxygenation, intracellular pH was monitored in cardiomyocytes exposed to cariporide to block NHE activity. CORM-3 inhibited alkalinisation and this effect was blocked by PD098059 and 5-HD. In conclusion, CORM-3 protects the cardiomyocyte against hypoxia-reoxygenation injury by inhibiting a bicarbonate transporter at reoxygenation, probably the Na+/HCO3- symporter. This cardioprotective effect of CORM-3 requires the activation of mKATP channels and the activation of MEK1/2.

Keywords: Carbon monoxide; Cardiomyocytes; Hypoxia-reoxygenation; pH.

MeSH terms

  • Animals
  • Carbon Monoxide / metabolism
  • Cell Hypoxia / drug effects
  • Cell Survival / drug effects
  • Cells, Cultured
  • Culture Media / chemistry
  • Decanoic Acids / pharmacology
  • Disease Models, Animal
  • Drug Evaluation, Preclinical
  • Flavonoids / pharmacology
  • Humans
  • Hydrogen-Ion Concentration
  • Hydroxy Acids / pharmacology
  • KATP Channels / antagonists & inhibitors
  • KATP Channels / metabolism
  • MAP Kinase Kinase 1 / metabolism
  • MAP Kinase Kinase 2 / metabolism
  • Male
  • Mice
  • Mitochondria / chemistry
  • Mitochondria / drug effects
  • Mitochondria / pathology
  • Myocardial Reperfusion Injury / pathology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocytes, Cardiac / cytology
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / pathology
  • Organometallic Compounds / pharmacology*
  • Organometallic Compounds / therapeutic use
  • Primary Cell Culture
  • Protective Agents / pharmacology*
  • Protective Agents / therapeutic use

Substances

  • Culture Media
  • Decanoic Acids
  • Flavonoids
  • Hydroxy Acids
  • KATP Channels
  • Organometallic Compounds
  • Protective Agents
  • tricarbonylchloro(glycinato)ruthenium(II)
  • 5-hydroxydecanoic acid
  • Carbon Monoxide
  • MAP Kinase Kinase 1
  • MAP Kinase Kinase 2
  • Map2k1 protein, mouse
  • Map2k2 protein, mouse
  • 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one